[1]徐俊波 黄刚 蔡琳 余秀琼 刘汉雄 吴镜.2019 ESC-HFA心衰病人新型降糖药应用及安全性立场声明的解读[J].心血管病学进展,2020,(4):408-413.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.020]
　XU Junbo,HUANG Gang,CAI Lin,et al.Interpretation of the 2019 ESC-HFA Position Paper on the Role and Safety of New Glucose Lowering Drugs in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2020,(4):408-413.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.020]
点击复制

2019 ESC-HFA心衰病人新型降糖药应用及安全性立场声明的解读()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年4期
页码:
408-413
栏目:
指南解读
出版日期:
2020-04-25

文章信息/Info

Title:
Interpretation of the 2019 ESC-HFA Position Paper on the Role and Safety of New Glucose Lowering Drugs in Patients with Heart Failure
作者:
徐俊波 黄刚 蔡琳 余秀琼 刘汉雄 吴镜
(成都市心血管病研究所 成都市第三人民医院心血管内科 西南交通大学附属医院,重庆医科大学附属成都第二医院,四川 成都 610031)
Author(s):
XU Junbo;  HUANG Gang;  CAI Lin;  Yu Xiuqiong;  Liu Hanxiong;  Wu Jing

 (Department of Cardioiogy, The Third People’s Hospital of Chengdu,Cardiovascular Disease Research Institute of Chengdu, Clinical College of Southwest Jiaotong University, The Second Affiliated Chengdu Clinical College of Chongqing Medical University,Chengdu 610031,Sichuan,China)

DOI:
10.16806/j.cnki.issn.1004-3934.2020.04.020

参考文献/References:

[1] Seferovi PM,Petrie MC,Filippatos GS,et al. Type 2 diabetes mellitus and heart failure:a position statement from the Heart Failure Association of the European Society of Cardiology [J]. Eur J Heart Fail,2018,20(5):853-872.
[2] 中华医学会糖尿病学分会. 中国 2 型糖尿病防治指南(2017 年版) [ J]. 中华糖尿病杂志,2018,10(1):4-67.
[3] 王华,李莹莹,柴坷,等. 中国住院心力衰竭患者流行病学及治疗现状[ J]. 中华心血管病杂志,2019,47(11):865-874.
[4] Seferovi PM,Petrie MC,Filippatos GS,et al. European Society of Cardiology Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure[J]. Eur J Heart Fail,2018,20(5): 853-872.
[5] Zelniker TA,Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors. JACC State-of-the-Art Review[J]. JACC,2020,74 (4):422-434.
[6] 张廷杰,徐俊波,黄刚. 源于证据,指导实践:美国 2014 成人高血压循证管 理指南管窥[J]. 中华高血压杂志,2014,22(1):17-23.
[7] 张廷杰,徐俊波. “循指南医学冶是实施循证医学的最佳途径[J]. 中华高血 压杂志,2010,18(4):301-303.
[8] Cosentino F,Grant PJ,Aboyans V,et al. 2019 ESC Guidelines on diabetes, pre-diabetes,and cardiovascular diseases developed in collaboration with the EASD[J]. Eur Heart J,2020,41(2):255-323.
[9] Davies MJ,D Alessio DA,Fradkin J,et al. Management of hyperglycaemia in type 2 diabetes,2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [J]. Diabetologia,2018,61(12):2461-2498.
[10] Buse JB,Wexler DJ,Tsapas A,et al. 2019 update to:management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [J]. Diabetologia,2020,63(2):221-228.
[11] 徐俊波,黄刚,蔡琳,等. 2019 ESC-HFA 射血分数保留性心力衰竭诊断共识 的解读[J]. 心血管病学进展,2019,40(9):1193-1195.

备注/Memo

备注/Memo:
基金项目：成都市科技局项目(11PPYB034SF-289)
收稿日期：2020-02-03
通讯作者：徐俊波，E-mail: xujunbo2000@sina.com
更新日期/Last Update: 2020-07-29